Smithkline Diagnostics, Inc. v. Helena Laboratories Corporation, Defendant/cross-Appellant

926 F.2d 1161, 17 U.S.P.Q. 2d (BNA) 1922, 1991 U.S. App. LEXIS 2868, 1991 WL 22947
CourtCourt of Appeals for the Federal Circuit
DecidedFebruary 26, 1991
Docket90-1002, 90-1021
StatusPublished
Cited by151 cases

This text of 926 F.2d 1161 (Smithkline Diagnostics, Inc. v. Helena Laboratories Corporation, Defendant/cross-Appellant) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Smithkline Diagnostics, Inc. v. Helena Laboratories Corporation, Defendant/cross-Appellant, 926 F.2d 1161, 17 U.S.P.Q. 2d (BNA) 1922, 1991 U.S. App. LEXIS 2868, 1991 WL 22947 (Fed. Cir. 1991).

Opinion

NIES, Chief Judge.

SmithKline Diagnostics, Inc. (SKD) appeals the judgment of the United States District Court for the Eastern District of Texas, SmithKline Diagnostics Inc. v. Helena Laboratories Corp., 12 USPQ2d 1375 (E.D.Tex.1989), awarding SKD $625,-461.06 against Helena Laboratories Corporation to compensate for Helena’s infringement of SKD’s U.S. Patent No. 4,365,970 (the ’970 patent). The award was based upon a 25% royalty on the selling price of Helena’s infringing product plus interest. SKD appeals, urging that the district court wrongly denied SKD a greater amount calculated on the basis of SKD’s lost profits and also wrongly denied costs to SKD. Helena cross-appeals, asserting that the amount of the award bears no rational relationship to the evidence in the record and seeks to have it based on 3% as a reasonable royalty. We affirm.

I

BACKGROUND

SKD owns the ’970 patent for a specimen test slide and method for detecting occult (hidden or invisible) blood in fecal matter. The invention is marketed under the trademark HEMOCCULT, and it is useful in the early diagnosis of a variety of gastroente-rological diseases including colorectal cancer. Helena markets various specimen test slides under the trademark COLOSCREEN. Only Helena’s COLOS-CREEN specimen test slide containing hemoglobin has been held to infringe SKD’s ’970 patent. See SmithKline Diagnostics, Inc. v. Helena Laboratories Corp., 859 F.2d 878, 891, 8 USPQ2d 1468, 1479 (Fed.Cir.1988) (containing a thorough discussion of the ’970 patent and its underlying technology). In this appeal we are called upon to review the amount awarded by the district court as damages upon the remand of the case following our prior decision.

SKD sought to have damages calculated on the basis of its lost profits. The court concluded, however, that SKD failed to prove its damages under this theory. The district court found that SKD did not show “even a slight or reasonable possibility, let alone a reasonable probability, that it would have made the sales of [HEMOCCULT slides] but for the sales by Helena.” SKD, 12 USPQ2d at 1380. In reaching that conclusion the district court found that: (1) acceptable, noninfringing substitutes existed for SKD’s HEMOCCULT slide; and (2) SKD did not establish that it had the manufacturing capacity or had access to the manufacturing capacity needed to cover the increased demand. Further, even assuming SKD would have made Hel *1163 ena’s sales, the district court rejected as incredible SKD’s proof as to the amount of profit it would have made, absent Helena’s infringement.

In view of SKD’s failure to prove lost profit damages, the district court turned to ascertainment of a reasonable royalty for the infringement. In this connection, the court considered the evidence that SKD was unwilling to license its patent; that Helena competed with lower priced competitors; Helena’s profit, market share and sales strategy; the presence of acceptable, noninfringing substitutes; other royalty rates paid by Helena; and testimony of witnesses for each party as to a reasonable royalty. The court expressed its uncertainty as to whether it was restricted to fixing damages based on the evidence proffered by one of the parties as to a specific percentage asserted to be a reasonable royalty, or whether it was free to exercise its own independent judgment and to determine a reasonable royalty based on the court’s evaluation of all of the evidence. The court solved this problem by making findings on each basis. The district court stated that, if forced to choose between the precise figures, Helena’s proof of 3% as a reasonable royalty was more credible than SKD’s proof of 48%. Specifically it stated:

The Court rejects Mr. Kay’s conclusion of one-half SKD’s lost profit, which amounts to a royalty of about 48% of Helena’s selling price, as unreasonable. Helena offered expert testimony, through former Commissioner Schuyler, based on the two existing Helena licenses, that a reasonably [sic] royalty in this case would not exceed 3% of the selling price of Helena's slides. The Court credits the testimony of former Commissioner Schuyler....
Fifty percent of SKD’s profit [i.e., 48% of Helena’s price], the “reasonable royalty” theory urged by SKD, is not credible as a reasonable royalty because of all the factors considered by the Court and is expressly rejected. Considering all the evidence as a whole, that amount would be a windfall to SKD and a penalty to Helena, and it is too large to reasonably compensate the patent owner for its proven damages.

SKD, 12 USPQ2d at 1379, 1381. The district court went on to find alternatively:

[I]f the Court is entitled to exercise its own independent judgment, based on the evidence as a whole, then the Court finds and concludes that a damage award adequate to compensate SKD for the infringement is 25% of Helena’s selling price.

SKD, 12 USPQ2d at 1381. Concluding ultimately that it was not restricted to selecting either of the specific figures proffered by the parties, the district court entered a damage award of $395,800.25 based on 25% of Helena’s total sales of infringing goods plus prejudgment interest for a total of $625,461.06. SKD now challenges the district court’s rejection of its proof of damages based on a claim of lost profits, whereas Helena maintains that the court erred in awarding damages based on 25% rather than 3% of Helena’s sales. SKD also seeks to overturn the denial of costs.

II

ISSUES

1. Whether the district court’s findings that SKD failed to establish the factors supporting lost profits as the measure of its damages are clearly erroneous.

2. Whether the district court was restricted to 3% as a reasonable royalty.

3. Whether the district court’s award calculated on a 25% royalty was insufficiently explained or is clearly erroneous.

4. Whether the district court abused its discretion in denying SKD costs.

III

STANDARD OF REVIEW

Section 284 of the 1952 Patent Act provides: “Upon finding for the claimant the court shall award the claimant damages adequate to compensate for the infringement, but in no event less than a reasonable royalty for the use made of the invention by the infringer_” 35 U.S.C. § 284

*1164 (1988). Through section 284, “Congress sought to ensure that the patent owner would in fact receive full compensation for ‘any damages’ he suffered as a result of the infringement.” General Motors Corp. v. Devex Corp., 461 U.S. 648, 654-55, 103 S.Ct. 2058, 2062, 76 L.Ed.2d 211, 217 USPQ 1185, 1188 (1983).

Damages is the amount of loss to a patentee. Aro Mfg. Co. v. Convertible Top Replacement Co., 377 U.S. 476, 505, 84 S.Ct.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Warsaw Orthopedic, Inc. v. Nuvasive, Inc.
778 F.3d 1365 (Federal Circuit, 2015)
Gaylord v. United States
777 F.3d 1363 (Federal Circuit, 2015)
Aqua Shield v. Interpool Pool Cover Team
774 F.3d 766 (Federal Circuit, 2014)
ClearValue, Inc. v. Pearl River Polymers, Inc.
735 F. Supp. 2d 560 (E.D. Texas, 2010)
LG Display Co., Ltd. v. AU Optronics Corp.
722 F. Supp. 2d 466 (D. Delaware, 2010)
Lucent Technologies, Inc. v. Gateway, Inc.
580 F.3d 1301 (Federal Circuit, 2009)
Heeling Sports Ltd. v. U.S. Furong International, Inc.
319 F. App'x 905 (Federal Circuit, 2009)
Bowling v. Hasbro, Inc.
582 F. Supp. 2d 192 (D. Rhode Island, 2008)
Mars, Inc. v. Coin Acceptors, Inc.
527 F.3d 1359 (Federal Circuit, 2008)
RRK Holding Co. v. Sears, Roebuck and Co.
563 F. Supp. 2d 832 (N.D. Illinois, 2008)
Mitutoyo Corp. v. Central Purchasing, LLC
499 F.3d 1284 (Federal Circuit, 2007)
Bank of America, FSB v. Doumani
495 F.3d 1366 (Federal Circuit, 2007)
Bernhardt L.L.C. v. Collezione Europa USA, Inc.
436 F. Supp. 2d 739 (M.D. North Carolina, 2006)
Sunbeam Products, Inc. v. Wing Shing Products (BVI) Ltd.
153 F. App'x 703 (Federal Circuit, 2005)
Harris Corporation v. Ericsson, Inc.
417 F.3d 1241 (Federal Circuit, 2005)
Home Savings of America, Fsb v. United States
399 F.3d 1341 (Federal Circuit, 2005)
Fuji Photo Film Co., Ltd. v. Jazz Photo Corp.
394 F.3d 1368 (Federal Circuit, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
926 F.2d 1161, 17 U.S.P.Q. 2d (BNA) 1922, 1991 U.S. App. LEXIS 2868, 1991 WL 22947, Counsel Stack Legal Research, https://law.counselstack.com/opinion/smithkline-diagnostics-inc-v-helena-laboratories-corporation-cafc-1991.